<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="43374">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01694225</url>
  </required_header>
  <id_info>
    <org_study_id>BCC-BRE-12-Adherence</org_study_id>
    <nct_id>NCT01694225</nct_id>
  </id_info>
  <brief_title>Estimating the Adherence Rate of a Monthly Bubble Package Among Patients Prescribed Adjuvant Endocrine Therapy in Breast Cancer Survivors</brief_title>
  <official_title>Estimating the Adherence Rate of a Monthly Bubble Package Among Patients Prescribed Adjuvant Endocrine Therapy in Breast Cancer Survivors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>James Graham Brown Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>James Graham Brown Cancer Center</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to establish the feasibility of using a monthly bubble package to improve
      compliance rates among women prescribed adjuvant endocrine therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study uses Bubble packaging to provide a cost effective way to improve compliance and
      help direct further interventions to ensure adherence in women on anti-estrogen therapy for
      breast cancer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>new to adjuvant hormone treatment</arm_group_label>
    <description>Patients new to adjuvant hormone treatment (&lt; 12 months)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>adjuvant hormonal treatment-intermediate</arm_group_label>
    <description>Patients in intermediate years of adjuvant hormonal treatment (12 - 36 months)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>adjuvant hormonal treatment-late years</arm_group_label>
    <description>Patients in late years of adjuvant hormonal treatment (37 - 60 months)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Bubble packaging of subjects prescription</intervention_name>
    <description>Monthly bubble packaging among women prescribed anti-estrogens</description>
    <arm_group_label>new to adjuvant hormone treatment</arm_group_label>
    <arm_group_label>adjuvant hormonal treatment-intermediate</arm_group_label>
    <arm_group_label>adjuvant hormonal treatment-late years</arm_group_label>
    <other_name>anti-estrogen therapy</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women on anti-estrogen therapy for breast cancer
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older

          -  Estrogen receptor positive (&gt; 1%  estrogen expression) by immunohistochemistry

          -  Invasive breast cancer (stage I, II, III) or DCIS considered for adjuvant endocrine
             therapy

        Exclusion Criteria:

          -  Patients with metastatic disease (stage IV)

          -  Patients less than 18 years of age

          -  Prisoners

          -  Patients are unable to fill prescriptions at the BCC pharmacy due to insurance
             limitations or personal preference
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth C Riley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>James Graham Brown Cancer Center- U of Louisville</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>James Graham Brown Cancer Center-University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth C Riley, MD</last_name>
      <phone>502-562-3429</phone>
    </contact>
    <contact_backup>
      <last_name>Belma Kantadzic</last_name>
      <phone>502-562-3429</phone>
    </contact_backup>
    <investigator>
      <last_name>Elizabeth C Riley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 19, 2014</lastchanged_date>
  <firstreceived_date>September 23, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Anti-estrogen therapy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Estrogen Antagonists</mesh_term>
    <mesh_term>Estrogen Receptor Modulators</mesh_term>
    <mesh_term>Estrogens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
